Agellum

Agellum is a biotechnology company focused on developing regenerative medicines through in vivo cellular reprogramming. Founded by pioneers from the Gladstone Institutes and UCSF, the company utilizes a proprietary small molecule platform to convert resident non-muscle cells, such as fibroblasts, into functional cardiomyocytes within the heart. This approach aims to repair damaged cardiac tissue and restore heart function in patients suffering from heart failure or following a myocardial infarction. Agellum's technology represents a significant shift from traditional cell transplantation toward direct, chemical-induced tissue regeneration. The company is currently advancing its lead programs through the pre-clinical stage with backing from prominent life science venture capital firms.